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1 Introduction  
The startling and unexpected result of the UK referendum held on 23 June 2016, in 
which a narrow majority of British voters opted to leave the European Union (EU), the 
so-called ‘Brexit’, has presented the pharmaceutical industry and their academic 
collaborators with a major challenge. The issue at stake is the UK’s exit from the 
European Medicines Agency (EMA) and the decision of the European Commission 
(EC) to move the headquarters of this body from London to Amsterdam by 30 March 
2019 [1]. It is neither the remit of this editorial to debate the reasons for the outcome 
of the referendum, nor to comment on the Remainer versus Leaver combat that has 
raged ever since. However, rather than succumb to the despair that permeates some 
of the commentariat, exemplified by the concern that patients may die because of the 
UK‘s ejection from the EMA and resulting loss of access to new drugs [2], it is our 
belief that Britain with Europe should seek to turn Brexit to mutual advantage. This will 
necessarily require skilful negotiation and a determination by all parties to 
compromise. It is unhelpful at this stage to proffer [3] precise figures for the extra 
expenditure incurred (i.e. by the UK, EU and pharma) if the UK becomes completely 
independent of the EMA, when it need not.  
 
2 Evaluating the Efficacy and Safety of New Medicines  
Following the discovery and development of a new drug, the need for strict evaluation 
of therapeutic effectiveness and safety prior to extensive clinical application is 
axiomatic. Determining efficacy requires nuanced reviews of data from animal 
experiments and clinical trials. Safety is paramount given past catastrophes, most 
notoriously, but not limited to, thalidomide (1959). However, establishing complete 
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safety of every therapeutic agent is illusory because even the finest regulatory system 
cannot avoid such reverses. The assessment of the balance of risks and benefits of a 
therapy is multi-factorial and requires expert, sometimes subjective, judgement. The 
complexities of human metabolic processes can present major challenges in the 
toxicological evaluation of a new chemical entity. Mechanistic toxicology is still a 
developing science and some lessons have been learned only after the widespread 
prescription of a drug, later withdrawn because of an adverse reaction. Reliance on 
animal models has misled investigators as with the thiazolidinone troglitazone, a 
treatment for type II diabetes, that was found to cause liver damage in ~2% of patients, 
resulting in withdrawal of the drug only after up to 2 million patients were exposed in 
the period 1997-2000 [4]. The evaluation of a drug’s safety is never ending  ongoing 
research on the mechanism of the hepatotoxicity of troglitazone is relevant to 
thiazolidinones still in clinical use.  
 
3 Drug Regulatory Bodies 
The genesis of the modern approach to the evaluation of new medicines is well 
illustrated for the United States by the origins of the Food & Drug Administration (FDA). 
Already in the 19th Century, driven by the antics of ‘snake oil salesmen’, the Chemistry 
Division of the US Department of Agriculture was testing drugs claimed to be effective 
human medicines, but with the actual chemical composition and dubious branding 
being issues of particular concern [5]. The organisation was rebadged as the FDA in 
1930, with growing reach and powers that continued apace, and led to the multifaceted 
body existing now, managing an annual budget of nearly $5 billion (of which $1.4 
billion was allocated to the Center for Drug Evaluation and Research: 2016 data [6]) 
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and with a workforce of ~ 15,000 (~ 3600 assigned to ‘drug evaluation research’ and 
270 to ‘toxicological research’ [7]). The FDA acted on behalf of a population of 321 
million in 2016.  
The EMA, the European counterpart of the FDA, was set up in 1995 to coordinate drug 
regulation across the European Union (population ~ 500 million), the primary focus 
being safety and efficacy of new medicines [8]. The resources of member states were 
pooled and channelled through 7 committees, with those concerning ‘Medicinal 
Products for Human Use’ and ‘Orphan Medicinal Products’, the latter focussed on 
treatments for less common diseases, being of most relevance to this editorial. Each 
country has its own national body or bodies, which are the Medicines and Healthcare 
Products Regulatory Agency (MHRA) and the National Institute for Health and Care 
Excellence (NICE) for the UK. NICE liaises with the EMA and determines the 
effectiveness versus cost of a new drug, which is especially important for the UK’s 
publicly funded National Health Service (NHS). The EMA’s annual budget of €323 
million and workforce of 890 (2015 data) appears to be substantially below that of the 
FDA, despite the EMA’s scope embracing approximately one third of the world’s new 
medicines.  
Both the EMA and FDA have been subject to several criticisms, with funding from the 
pharmaceutical industry allegedly compromising their independence [9] and time 
taken to approve new medicines (see below) being matters of contention. Thus, a 
surprising high proportion of EMA income (83% compared to 45% for the FDA) derives 
from the pharmaceutical industry, the products of which it is presumed to regulate. The 
slower approval of new medicines by the EMA compared to the FDA (478 days on 
average for the EMA as opposed to 304 days for the FDA [10]) may possibly be 
explained by the EMA’s relatively small workforce. One may question whether EMA 
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committees need a representative from every EU country, rather than being 
streamlined with a smaller group of the best expertise available. Unfortunately, 
pressure from politicians, e.g. questioning the speed and import of evaluations, as well 
as populist media campaigns, may perturb the decision-making process adversely 
[11]. The difference between the EMA and FDA approval times is quite small 
compared to the overall time between the concept for a new medicine and its eventual 
clinical use. For areas of unmet need, many cancers for example, there are already 
robust mechanisms for accelerating the approval process [10].  
There are other individual countries, both smaller and larger in population than the UK, 
that have perfectly viable, standalone drug regulatory bodies analogous to the FDA, 
e.g. Australia (Therapeutic Goods Administration), Japan (Pharmaceuticals and 
Medical Devices Agency) and Switzerland (Swiss Agency for Therapeutic Products), 
with the latter’s confidentially agreement with the EMA [12] perhaps being a template 
for future UK-EMA cooperation. 
 
4 Some Challenges of Brexit 
There are potential severe consequences of Brexit for the effectiveness of 
pharmaceutical research in the UK and the rest of Europe. Along with the USA, Europe 
is at the forefront of medicines research and has contributed hugely to past and current 
innovations in drug therapy. Although many historical discoveries preceded the 
formation of the EU [13], pan-European research has been stimulated and facilitated 
by the EU, via free movement of people, goods and services, and opportunities for 
funded research (e.g. Horizon 2020), all of which could be compromised by Brexit. It 
has been highlighted that UK pharmaceutical companies are struggling to recruit 
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talented researchers from Europe since the referendum [14]. Also worrisome is the 
planned exit, if not flight, of academics and healthcare professionals since the Brexit 
vote [15]. This may be partly due to misconceptions about the reasons for the Brexit 
vote, fostered by questionable academic research [16], as well as anxiety about what 
the future may harbour. However, UK employment policies have not changed (yet), 
and it is inconceivable that suitably qualified individuals will be barred from working in 
the UK post-Brexit – but nevertheless concern is widespread and needs to be allayed.  
 
5 Expert Opinion  
So how do we solve the conundrum of Brexit versus the EMA? The Brexit decision 
has prompted fears that the whole process of drug discovery, development and 
regulation will be severely compromised in the UK [17], with knock-on effects for the 
rest of Europe. Whatever the outcome of negotiations, additional expenditure that 
could have otherwise supported new research is almost inevitable. Changes in 
regulatory policies post-Brexit could lead to extra expenditure because drug 
companies will need to prepare additional submissions to the putative new UK 
regulatory body as well as to the EMA [3]. We believe that while the costs should be 
minimal, companies need to plan for such an eventuality and greater costs may be 
incurred if policy makers do not provide clarity and reassurance imminently. The 
decision to relocate the EMA to Amsterdam seems to have been rather hastily 
reached, but it is probably the best location, if only considering this city’s excellent 
public transportation with fast connection to Schiphol airport. Fretting, as some 
commentators have [1], that London has lost 36,000 hotel beds to Amsterdam, is a 
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side-show in the wider context. Rather, the move to Amsterdam should inspire the 
EMA to improve its market approval process [18].  
The future relationship between the UK and EMA should aim for closer interactions 
between drug developers and regulators. It is vital that those involved in the discovery 
and development of medicines can anticipate what the likely future regulatory 
requirements will be, thus providing the best chance of bringing safer, more efficacious 
new treatments to market. This will be facilitated by regulatory bodies that constantly 
exchange information and opinions to maximise consistency in policies. Among 
possible scenarios are that the UK remains a member of the EMA, by providing 
appropriate remuneration, or that the EMA devolves selected activities to a new UK 
regulator. It is also essential that the UK continues to participate in European consortia 
such as the Innovative Medicines Initiative, which seeks to accelerate access to new 
medicines, especially those with an unmet need [19]. Negotiators need to remember 
that ultimately it is the patients across Europe that matter.  
The current regulatory processes for medicines in Europe and the USA are not perfect 
and Brexit provides an opportunity for a timely EMA rethink. We posit that whilst Brexit 
presents many issues to be addressed, these should be eminently manageable if 
negotiations were more pragmatic and less de rigueur. There is an opportunity for all 
sides to reflect on the European pharmaceutical landscape, but let’s not dismantle 
what is fundamentally great and good. We see the goal as working towards an efficient 
and productive new relationship between the UK and the rest of Europe, always 
putting the needs of the patient first, and discarding narrow sectional interests. 
Discourse and cooperation between European scientists and medical practitioners 
has been a prominent feature since the early 19th Century, if not long before, and it is 
ridiculous to think that Brexit will stifle that [13].  
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Several of the issues discussed here parallel those advanced for other sectors and 
many of the matters that need to be addressed are generic. There is a risk that 
concerns relating to the pharmaceutical industry will be of low priority in negotiations, 
relative to say financial services. However, the wider negotiations will hopefully offer 
early solutions, or at least set a precedent and provide reassurance as to how the 
future terrain for the regulation of drug development might evolve. Our opinion is that 
there must a synergistic relationship between the EMA and future UK regulator, if the 
latter is what transpires, thus avoiding duplication of effort and unnecessary costs. 
Ultimately, will common-sense prevail? Given the crisis of the emergence of resistant 
pathogens, abrogating many current treatments [20], unabated drug discovery in 
Europe is too important to fall on the sword of political infighting. The Brexit negotiating 
teams must realise that all European citizens will suffer without the UK continuing to 
be being intimately involved in every aspect of drug discovery, evaluation and 
regulation. Hopefully, we can look back in say 5 years’ time and marvel how the myriad 
of current issues were equitably resolved.  
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